MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) CFO Gregory P. Hanson sold 11,232 shares of MabVax Therapeutics stock in a transaction on Friday, January 12th. The shares were sold at an average price of $0.96, for a total value of $10,782.72. Following the sale, the chief financial officer now directly owns 478,365 shares of the company’s stock, valued at approximately $459,230.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) opened at $0.87 on Friday. The stock has a market capitalization of $19.90, a price-to-earnings ratio of -0.25 and a beta of 1.52. MabVax Therapeutics Holdings, Inc. has a 12-month low of $0.43 and a 12-month high of $3.57. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.80.
MabVax Therapeutics (NASDAQ:MBVX) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter. equities analysts forecast that MabVax Therapeutics Holdings, Inc. will post -3.01 EPS for the current year.
An institutional investor recently bought a new position in MabVax Therapeutics stock. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned about 12.33% of MabVax Therapeutics at the end of the most recent quarter. 12.87% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells $10,782.72 in Stock” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/19/mabvax-therapeutics-holdings-inc-mbvx-cfo-sells-10782-72-in-stock.html.
MabVax Therapeutics Company Profile
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.